Significant decrease in efficacy against new Sarscov2 variants

While new dominant sarscov2 variants of concern taking over the globe, vaccine advocates continue to claim efficacy against dominant sarscov2 variants despite significant 2.2-6-8X decline in neutralizing antibody ability. Thle T cell immunity against now predominant new variants(B1351; P.1 etc) is overstated. The reality is vaccines efficacy drops to 15-33% from 90s%. The study shows very low numbers of predominantly t helpers cd4 providing intercellular signaling and infection memory, but not a real defense while cytotoxic cd8 cells are produced&circulate in extremely low concentration https://www.nature.com/articles/doi:10.1038/s41590-021-00902-8.epdf?sharing_token=y0WEgaoLdZnRuk9g3cScn9RgN0jAjWel9jnR3ZoTv0MjkRwSpMek28RzrR1zrK1KfgP9Fv2XayaBGNTV4T83CelAAdUn1jDf-HB7zsKC92ktZLD21Qw4RjogtiekUkjsVd-fpPsx8ZY5fe6wOEmOyPh47ChyU1b1BvVmnVEUKRo%3D